Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MacDonald, P. E.
Right arrow Articles by Wheeler, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacDonald, P. E.
Right arrow Articles by Wheeler, M. B.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:S443-S447, 2002
© 2002 by the American Diabetes Association, Inc.


Section 5: Beta-Cell Stimulus-Secretion Coupling: Hormonal and Pharmacological Modulators

Glucagon-Like Peptide-1 Receptor Activation Antagonizes Voltage-Dependent Repolarizing K+ Currents in ß-Cells

A Possible Glucose-Dependent Insulinotropic Mechanism

Patrick E. MacDonald1, Anne Marie F. Salapatek1, and Michael B. Wheeler1,2

1 Department of Physiology, University of Toronto, Toronto, Ontario, Canada
2 Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Glucagon-like peptide-1 (GLP-1) acts through its G-protein-coupled receptor to enhance glucose-stimulated insulin secretion from pancreatic ß-cells. This is believed to result from modulation of at least two ion channels: ATP-sensitive K+ (KATP) channels and voltage-dependent Ca2+ channels. Here, we report that GLP-1 receptor signaling also regulates the activity of ß-cell voltage-dependent K+ (KV) channels, themselves potent glucose-dependent regulators of insulin secretion. GLP-1 receptor activation with exendin 4 (10-8 mol/l) in rat ß-cells antagonized KV currents by 43.3 ± 6.3%, whereas the GLP-1 receptor antagonist exendin 9-39 had no effect. The effect of GLP-1 receptor activation on KV currents could be replicated (current reduction of 55.7 ± 6.0%) by G-protein activation with GMP-PNP (10 nmol/l). The cAMP pathway antagonist Rp-cAMPS (100 µmol/l) prevented current inhibition by exendin 4, implicating cAMP signaling in GLP-1 receptor modulation of ß-cell KV currents. Finally, exendin 4 (10-8 mol/l) increased the amplitude (130 ± 5.7%) and duration (285 ± 15.9%) of the ß-cell depolarization response to current injection, independent of any effect on KATP or Ca2+ channels. The present results demonstrate that GLP-1 receptor signaling can antagonize ß-cell repolarization by reducing voltage-dependent K+ currents, an effect likely to contribute to GLP-1’s glucose-dependent insulinotropic effect.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. Muscelli, A. Mari, A. Natali, B. D. Astiarraga, S. Camastra, S. Frascerra, J. J. Holst, and E. Ferrannini
Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1144 - E1150.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. Liu, S. M. P. Jacobo, N. Hilliard, and G. H. Hockerman
Differential Modulation of Cav1.2 and Cav1.3-Mediated Glucose-Stimulated Insulin Secretion by cAMP in INS-1 Cells: Distinct Roles for Exchange Protein Directly Activated by cAMP 2 (Epac2) and Protein Kinase A
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 152 - 160.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. A. D'Alessio and T. P. Vahl
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.